Drug Trial Radar · NCT05192382
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Last checked: Nov 20, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
111
Actual
Start
Dec 17, 2021
Primary completion
Jan 20, 2024
Study completion Jun 2, 2026
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.
Conditions
- Acromegaly
Interventions
PaltusotineDrug
Paltusotine, tablets, once daily by mouth
PlaceboDrug
Placebo, tablets, once daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Biochemical Response in Insulin-like Growth Factor-1 (IGF-1) at the End of the Randomized Control Phase (EOR)Time frame: Week 24
Locations
57 sites in 15 countries. Site status is shown where the registry gives one.
Crinetics Study Site
Aurora, Colorado
Crinetics Study Site
Boston, Massachusetts
Crinetics Study Site
Columbus, Ohio
Crinetics Study Site
Portland, Oregon
Crinetics Study Site
Philadelphia, Pennsylvania
Crinetics Study Site
Pittsburgh, Pennsylvania
Crinetics Study Site
Buenos Aires, Argentina
Crinetics Study Site
CABA, Argentina
Crinetics Study Site
CABA, Argentina
Crinetics Study Site
Córdoba, Argentina
Crinetics Study Site
CABA, Buenos Aires, Argentina
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
São Paulo, Brazil
Crinetics Study Site
São Paulo, Brazil
Crinetics Study Site
Fortaleza, Ceará, Brazil
Crinetics Study Site
Belo Horizonte, Minas Gerais, Brazil
Crinetics Study Site
Curitiba, Paraná, Brazil
Crinetics Study Site
Botucatu, São Paulo, Brazil
Crinetics Study Site
Campinas, São Paulo, Brazil
Crinetics Study Site
Sofia, Bulgaria
Crinetics Study Site (b)
Beijing, Beijing Municipality, China
Crinetics Study Site
Guangzhou, Guangdong, China
Crinetics Study Site
Shijiazhuang, Hebei, China
Crinetics Study Site
Zhengzhou, Henan, China
Crinetics Study Site
Wuhan, Hubei, China
Crinetics Study Site
Changsha, Hunan, China
Crinetics Study Site
Jinan, Shandong, China
Crinetics Study Site
Xi’an, Shanxi, China
Crinetics Study Site
Chengdu, Sichuan, China
Crinetics Study Site
Hangzhou, Zhejiang, China
Crinetics Study Site
Marseille, France
Crinetics Study Site
Pessac, France
Crinetics Study Site
Toulouse, France
Crinetics Study Site
Aachen, Germany
Crinetics Study Site
Berlin, Germany
Crinetics Study Site
München, Germany
Crinetics Study Site
München, Germany
Crinetics Study Site
Würzburg, Germany
Crinetics Study Site
Athens, Greece
Crinetics Study Site (b)
Athens, Greece
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.